

K101011

MAY 24 2010

510(k) Summary

The 510(k) Summary is submitted in accordance with 21 CFR §807.92 and the requirements of the Safe Medical Device Act (SMDA) of 1990.

1. <u>Submitter's Name</u>	Abbott Vascular Inc.
2. <u>Submitter's Address</u>	26531 Ynez Road, Temecula, CA 92591
3. <u>Telephone</u>	(951) 914-3242
4. <u>Fax</u>	(951) 914-0339
5. <u>Contact Person</u>	Kay Setzer
6. <u>Date Prepared</u>	April 5, 2010
7. <u>Device Trade Name</u>	HI-TORQUE BALANCE MIDDLEWEIGHT UNIVERSAL Guide Wire Family
8. <u>Device Common Name</u>	Guide Wire
9. <u>Device Classification Name</u>	Catheter Guide Wire (DQX)
10. <u>Predicate Device Name</u>	HI-TORQUE BALANCE MIDDLEWEIGHT UNIVERSAL Guide Wire (K013833, cleared January 16, 2002), HI-TORQUE BALANCE MIDDLEWEIGHT UNIVERSAL II Guide Wire, (K072460, cleared April 11, 2008), HT PROGRESS Guide Wire (K091825, cleared Sept. 25, 2009)

11. Device Description

The HI-TORQUE BALANCE MIDDLEWEIGHT™ UNIVERSAL Guide Wire is a steerable guide wire available in a maximum diameter of 0.0137" and in lengths of 190 cm and 300 cm. The distal segment of the guide wire, up to the hypotube, is coated with hydrophilic coating to reduce friction for improved guide wire movement within the catheter. The distal tip is offered in a straight shapeable configuration and a pre-shaped "J" configuration. The proximal core has a maximum diameter of 0.0137". The proximal end of the guide wire is coated with PTFE, which reduces friction of the wire within a catheter. The BMW™ Universal Guide Wire is DOC® extendable in the 190 cm lengths.

12. Indication for Use

To facilitate the placement of balloon dilatation catheters during percutaneous transluminal coronary angioplasty (PTCA) and percutaneous transluminal angioplasty (PTA). The wire is also intended to facilitate the placement of compatible stent devices during therapeutic intravascular procedures.

13. Technological Characteristics

Comparisons of the new and predicate devices show that the technological characteristics such as product performance, design and intended use are substantially equivalent to the current marketed predicate devices. The proposed device is similar in design and materials to the currently marketed product in that its core wire, tip coils, and solders remain the same. The hydrophilic coating has been changed but is similar to previously marketed devices.

14. Performance Data

In vitro bench testing, including tensile strength; torque strength, torqueability, coating adherence and integrity (particulate testing), and friction testing were conducted on the subject device. Biocompatibility testing was leveraged from predicate devices with similar materials. Biocompatibility tests included cytotoxicity, hemolysis, acute systemic toxicity, complement activation, coagulation, intracutaneous (intradermal) reactivity test, USP systemic injection test, sensitization, rabbit pyrogen test, LAL pyrogen, bacterial endotoxins, and *in vivo* thrombogenicity tests. The *in vitro* bench tests and the biocompatibility tests demonstrated that the HI-TORQUE BALANCE MIDDLEWEIGHT™ UNIVERSAL Guide Wire met all acceptance criteria and performed similarly to the predicate devices. No new safety or effectiveness issues were raised during the testing program and therefore, the HI-TORQUE BALANCE MIDDLEWEIGHT™ UNIVERSAL Guide Wire may be considered substantially equivalent to the predicate devices.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room W-O66-0609
Silver Spring, MD 20993-0002

Abbott Vascular Inc.
c/o Ms. Kay Setzer
Senior Regulatory Affairs Associate
26531 Ynez Road
Temecula, CA 92590

MAY 24 2010

Re: K101011

Trade Name: HI-TORQUE BALANCE MIDDLEWEIGHT UNIVERSAL Guide Wire Family
Regulation Number: 21 CFR 870.1330
Regulation Name: Catheter guide wire
Regulatory Class: Class II
Product Code: DQX
Dated: May 7, 2010
Received: May 10, 2010

Dear Ms. Setzer:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

Bram D. Zuckerman

[Signature]

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K101011

Device Name: HI-TORQUE BALANCE MIDDLEWEIGHT UNIVERSAL Guide Wire Family

Indications for Use:

To facilitate the placement of balloon dilatation catheters during percutaneous transluminal coronary angioplasty (PTCA) and percutaneous transluminal angioplasty (PTA). The wire is also intended to facilitate the placement of compatible stent devices during therapeutic intravascular procedures.

Prescription Use X AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE
OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Donna R. Veltman
(Division Sign-Off)
Division of Cardiovascular Devices

510(k) Number K101011